GLP-1 receptor agonists: mechanism and current research
GLP-1 (glucagon-like peptide-1) is an incretin hormone the gut releases after a meal. It binds the GLP-1 receptor on pancreatic beta cells and in the brain, where it raises glucose-dependent insulin release, slows gastric emptying, and signals satiety. Synthetic GLP-1 receptor agonists copy that signal with a longer half-life, which is why they anchor one of the most active areas of metabolic research.
The Veristas GLP-1 research catalog covers three generations of that chemistry. Understanding how they differ starts with counting receptors.
Single, dual, and triple agonism
Semaglutide activates one receptor, GLP-1R. It is the most studied molecule in the class and the reference point every newer agonist gets measured against.
Tirzepatide adds a second target. It activates both the GIP receptor and GLP-1R, a dual mechanism that engages two incretin pathways at once. Structural work published in Nature's Cell Discovery in 2024 mapped how a single peptide docks into both receptors.
Retatrutide adds a third. It is a triple agonist of the GLP-1, GIP, and glucagon receptors. The glucagon arm sets it apart: alongside the incretin effects, glucagon-receptor activity influences energy expenditure and hepatic metabolism. Retatrutide is investigational and not FDA-approved.
Survodutide takes a different pair, combining GLP-1 and glucagon receptor activity, and cagrilintide sits just outside the group as a long-acting amylin analogue often studied in combination with semaglutide.
What the research shows
Semaglutide and tirzepatide are approved drugs with large published trial programs (the STEP, SUSTAIN, SURPASS, and SURMOUNT series). Retatrutide and survodutide are still moving through clinical study, so the data on them is earlier and the picture is still forming. A 2025 review in the metabolic literature laid out the rationale for triple agonism as the step after dual agonists.
For a researcher, these molecules are not interchangeable. Receptor selectivity, binding affinity, and half-life all differ, and a study design that treats them as one class will miss what makes each one distinct.
Handling in the lab
All of these arrive as lyophilized powder and need reconstitution before use. Our reconstitution guide walks through solvent choice and concentration math. Store the sealed vial cold and protect it from light; peptide chains in this family degrade with repeated freeze-thaw cycles.
Every Veristas batch ships with a third-party Certificate of Analysis confirming identity and purity, which matters more here than in most classes because these are long, modified sequences where synthesis errors hide without mass spec. Our guide to reading a CoA covers what those numbers mean.
For in-vitro laboratory research only. Not for human or animal consumption. This summary is educational and does not describe or recommend any use in humans.
References: Structural insights into triple agonism at GLP-1R, GIPR and GCGR (Nature, Cell Discovery, 2024); Triple agonism-based therapies for obesity (narrative review, 2025).